Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias.
Luminari S, Goldaniga M, Ceccherelli F, Guffanti A, Bombardieri E, Marcheselli R, Cro L, Colombi M, Federico M, Baldini L. Luminari S, et al. Among authors: goldaniga m. Br J Haematol. 2003 Jun;121(5):772-4. doi: 10.1046/j.1365-2141.2003.04353.x. Br J Haematol. 2003. PMID: 12780792 Free article.
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. Baldini L, et al. Among authors: goldaniga m. J Clin Oncol. 2005 Jul 20;23(21):4662-8. doi: 10.1200/JCO.2005.06.147. J Clin Oncol. 2005. PMID: 16034042
Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F, Petrucci MT, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, Depaoli L, Baldini L. Rossi F, et al. Among authors: goldaniga m. Clin Cancer Res. 2009 Jul 1;15(13):4439-45. doi: 10.1158/1078-0432.CCR-08-3150. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509142
The clinical and biological features of a series of immunophenotypic variant of B-CLL.
Cro L, Ferrario A, Lionetti M, Bertoni F, Zucal N N, Nobili L, Fabris S, Todoerti K, Cortelezzi A, Guffanti A, Goldaniga M, Marcheselli L, Neri A, Lambertenghi-Deliliers G, Baldini L. Cro L, et al. Among authors: goldaniga m. Eur J Haematol. 2010 Aug;85(2):120-9. doi: 10.1111/j.1600-0609.2010.01454.x. Epub 2010 Apr 8. Eur J Haematol. 2010. PMID: 20408870
Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Gobbi PG, et al. Among authors: goldaniga m. Clin Cancer Res. 2005 Mar 1;11(5):1786-90. doi: 10.1158/1078-0432.CCR-04-1899. Clin Cancer Res. 2005. PMID: 15756000
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Ferrario A, Merli F, Luminari S, Stelitano C, Mannina D, Russo M, Mazza P, Marcheselli L, Goldaniga MC, Federico M, Baldini L; Gruppo Italiano per lo Studio dei Linfomi. Ferrario A, et al. Among authors: goldaniga mc. Ann Hematol. 2011 Mar;90(3):323-30. doi: 10.1007/s00277-010-1067-1. Epub 2010 Sep 17. Ann Hematol. 2011. PMID: 20848104 Clinical Trial.
43 results